HK1209621A1 - Inhibitors of the mir-15 family of micro-rnas - Google Patents

Inhibitors of the mir-15 family of micro-rnas Download PDF

Info

Publication number
HK1209621A1
HK1209621A1 HK15110356.0A HK15110356A HK1209621A1 HK 1209621 A1 HK1209621 A1 HK 1209621A1 HK 15110356 A HK15110356 A HK 15110356A HK 1209621 A1 HK1209621 A1 HK 1209621A1
Authority
HK
Hong Kong
Prior art keywords
mir
family
oligonucleotides
abundance
rnas
Prior art date
Application number
HK15110356.0A
Other languages
English (en)
Chinese (zh)
Inventor
Eva Van Rooij
Christina Dalby
Anita Seto
Original Assignee
MiRagen Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MiRagen Therapeutics, Inc. filed Critical MiRagen Therapeutics, Inc.
Publication of HK1209621A1 publication Critical patent/HK1209621A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK15110356.0A 2012-06-21 2013-06-21 Inhibitors of the mir-15 family of micro-rnas HK1209621A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261662772P 2012-06-21 2012-06-21
US201261662772P 2012-06-21
US201361780352P 2013-03-13 2013-03-13
US201361780352P 2013-03-13
PCT/US2013/046960 WO2013192486A1 (en) 2012-06-21 2013-06-21 Inhibitors of the mir-15 family of micro-rnas

Publications (1)

Publication Number Publication Date
HK1209621A1 true HK1209621A1 (en) 2016-04-08

Family

ID=49769409

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15110356.0A HK1209621A1 (en) 2012-06-21 2013-06-21 Inhibitors of the mir-15 family of micro-rnas

Country Status (17)

Country Link
US (1) US9163235B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2863956A4 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2015525081A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR20150036140A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN104540527A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR091539A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2013277033A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112014032239A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2876105A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA201590070A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK1209621A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2014DN10899A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MD (1) MD20150006A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX2014015641A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG11201408460UA (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW201406774A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2013192486A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9388408B2 (en) 2012-06-21 2016-07-12 MiRagen Therapeutics, Inc. Oligonucleotide-based inhibitors comprising locked nucleic acid motif
CN105189751B (zh) 2013-03-15 2019-04-23 米拉根医疗股份有限公司 桥接双环核苷
US10443044B2 (en) 2014-04-17 2019-10-15 Ips Heart Generating cardiac progenitor cells from pluripotent stem cells using isoxazole or isoxazole like compounds
JP6637961B2 (ja) 2014-08-04 2020-01-29 ミラゲン セラピューティクス， インコーポレイテッド Ｍｙｈ７ｂの阻害剤およびその使用
EP3177721A1 (en) 2014-08-07 2017-06-14 Regulus Therapeutics Inc. Targeting micrornas for metabolic disorders
AU2016209386A1 (en) 2015-01-20 2017-08-03 MiRagen Therapeutics, Inc. miR-92 inhibitors and uses thereof
WO2017219170A1 (zh) * 2016-06-19 2017-12-28 毛侃琅 特异抑制人 miRNA-29a 和 miR-424 表达的慢病毒载体的构建及其应用
CN110177544A (zh) 2016-11-29 2019-08-27 普尔泰克健康有限公司 用于递送治疗剂的外泌体
CN106692175A (zh) * 2016-12-26 2017-05-24 大连医科大学附属第二医院 miR‑665‑3p抑制物在制备防治缺血再灌注损伤药物中的应用
US10941403B2 (en) 2018-04-02 2021-03-09 Oregon Health & Science University Microrna inhibitors as anti-cancer therapeutics
US20220267778A1 (en) 2019-07-30 2022-08-25 Shionogi & Co., Ltd. Nucleic acid drug targeting murf1
WO2022018269A1 (en) * 2020-07-23 2022-01-27 Johann Wolfgang Goethe-Universität Frankfurt Combinatorial inhibition of mirnas for treatment of heart failure
CN113599540B (zh) * 2021-05-27 2023-05-23 山西医科大学 miRNA-195-5p在制备抑制或降低麦芽酚铝所致神经细胞损伤的试剂中的应用

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2447370B1 (en) 2001-09-28 2018-07-18 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. MicroRNA molecules
AU2003265978A1 (en) 2002-05-03 2003-11-17 Duke University A method of regulating gene expression
US7892793B2 (en) 2002-11-04 2011-02-22 University Of Massachusetts Allele-specific RNA interference
CN102304570B (zh) 2002-11-13 2015-01-21 托马斯杰斐逊大学 用于癌症诊断和治疗的组合物和方法
JP5479663B2 (ja) 2002-12-20 2014-04-23 セレラ コーポレーション 心筋梗塞に関連する遺伝的多型、その検出方法および使用
EP1592791A2 (en) 2003-02-10 2005-11-09 National Institute of Advanced Industrial Science and Technology Regulation of gene expression by dna interference
WO2005017111A2 (en) 2003-07-15 2005-02-24 The Trustees Of The University Of Pennsylvania Methods and systems for identifying micro-rna targets and synthesizing novel micro-rnas and uses of the same
WO2005013901A2 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
US8106180B2 (en) 2003-08-07 2012-01-31 Whitehead Institute For Biomedical Research Methods and products for expression of micro RNAs
WO2005017145A1 (ja) 2003-08-13 2005-02-24 Japan Biological Informatics Consortium 機能性ｒｎａが制御する被制御遺伝子の同定・予測方法及びその利用方法
EP1676914A4 (en) 2003-09-22 2007-10-10 Aichi Prefecture TYPE OF PATHOLOGICAL LYMPHOMA AND DIAGNOSTIC EVALUATION METHOD
CA2539654A1 (en) 2003-10-14 2005-05-06 Novartis Ag Oligonucleotide microarray
CA2545944A1 (en) 2003-11-13 2005-06-02 Board Of Regents, The University Of Texas System Inhibition of trp channels as a treatment for cardiac hypertrophy and heart failure
KR100860087B1 (ko) 2003-12-15 2008-09-25 포천중문의과대학교 산학협력단 인간 배아줄기세포에서 분리된 신규 ｍｉＲＮＡ
WO2005078096A2 (en) 2004-02-09 2005-08-25 University Of Massachusetts Dual functional oligonucleotides for use in repressing mutant gene expression
EP1713938A2 (en) 2004-02-09 2006-10-25 Thomas Jefferson University DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES
WO2005079397A2 (en) 2004-02-13 2005-09-01 Rockefeller University Anti-microrna oligonucleotide molecules
US8088902B2 (en) 2004-04-05 2012-01-03 The Rockefeller University DNA virus microRNA and methods for inhibiting same
US20050260648A1 (en) 2004-04-06 2005-11-24 Huffel Christophe V Method for the determination of cellular transcriptional
US20060134639A1 (en) 2004-04-06 2006-06-22 Huffel Christophe V Method for the determination of cellular transcriptional regulation
CN1961081B (zh) 2004-04-07 2012-09-05 埃克斯魁恩公司 用于定量微rna和小干扰rna的新方法
WO2005118806A2 (en) 2004-05-28 2005-12-15 Ambion, Inc. METHODS AND COMPOSITIONS INVOLVING MicroRNA
JP5192234B2 (ja) 2004-08-10 2013-05-08 アルナイラム ファーマシューティカルズ， インコーポレイテッド 化学修飾オリゴヌクレオチド
JP2008511678A (ja) 2004-09-02 2008-04-17 イェール ユニバーシティ マイクロｒｎａによるオンコジーンの調節
FR2877350B1 (fr) 2004-11-03 2010-08-27 Centre Nat Rech Scient IDENTIFICATION ET UTILISATION DE miRNAs IMPLIQUES DANS LA DIFFERENCIATION DE CELLULES ISSUES D'UNE LEUCEMIE MYELOIDE
EP2281889B1 (en) 2004-11-12 2014-07-30 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
WO2006063356A1 (en) 2004-12-10 2006-06-15 Isis Phamaceuticals, Inc. Regulation of epigenetic control of gene expression
US20060185027A1 (en) 2004-12-23 2006-08-17 David Bartel Systems and methods for identifying miRNA targets and for altering miRNA and target expression
US20060166920A1 (en) 2005-12-27 2006-07-27 Regents Of The University Of Michigan Oligonucleotide based therapeutics
EP1838870A2 (en) 2004-12-29 2007-10-03 Exiqon A/S NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF MICRORNAS AND THEIR TARGET MRNAs
US8071306B2 (en) 2005-01-25 2011-12-06 Merck Sharp & Dohme Corp. Methods for quantitating small RNA molecules
US20070065840A1 (en) 2005-03-23 2007-03-22 Irena Naguibneva Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAS and their target mRNAS
JP2006292367A (ja) 2005-04-05 2006-10-26 Mitsubishi Rayon Co Ltd ｍｉＲＮＡ検出用マイクロアレイ
WO2006108582A2 (en) 2005-04-15 2006-10-19 Cenix Bioscience Gmbh Human marker genes and agents for diagnosis, treatment and prophylaxis of cardiovascular disorders and artherosclerosis
CN101203611B (zh) 2005-04-19 2013-08-14 巴斯福植物科学有限公司 控制基因表达的改良方法
SI2002003T1 (sl) 2005-05-27 2016-05-31 Ospedale San Raffaele S.R.L. Genski vektor, ki vsebuje mi-RNA
CA2610265A1 (en) 2005-05-31 2007-05-10 Cold Spring Harbor Laboratory Methods for producing micrornas
US20070054287A1 (en) 2005-05-31 2007-03-08 Applera Corporation Method for identifying medically important cell populations using micro rna as tissue specific biomarkers
WO2006133022A2 (en) 2005-06-03 2006-12-14 The Johns Hopkins University Compositions and methods for decreasing microrna expression for the treatment of neoplasia
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
US20070123482A1 (en) 2005-08-10 2007-05-31 Markus Stoffel Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
CN101426912A (zh) 2005-08-17 2009-05-06 瑟纳治疗公司 介导rna干扰的化学修饰短干扰核酸分子
US8481505B2 (en) 2005-09-12 2013-07-09 The Ohio State University Research Foundation Compositions and methods for the diagnosis and therapy of BCL2-associated cancers
US20070092882A1 (en) 2005-10-21 2007-04-26 Hui Wang Analysis of microRNA
WO2007056826A1 (en) 2005-11-21 2007-05-24 Johnson & Johnson Research Pty Limited Multitargeting interfering rnas and methods of their use and design
WO2007087451A2 (en) 2006-01-25 2007-08-02 University Of Massachusetts Compositions and methods for enhancing discriminatory rna interference
WO2007092181A2 (en) 2006-01-26 2007-08-16 Unversity Of Massachusetts Compositions and methods for modulating translational repression
JP2009524679A (ja) 2006-01-26 2009-07-02 ユニバーシティ オブ マサチューセッツ 治療に用いるためのｒｎａサイレンシング物質およびその効率的な送達のためのナノ輸送体
CA2640058C (en) 2006-01-27 2018-04-24 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of micrornas
EP1986697B1 (en) 2006-02-17 2016-06-29 GE Healthcare Dharmacon, Inc. Compositions and methods for inhibiting gene silencing by rna interference
EP2522748A1 (en) 2006-03-02 2012-11-14 The Ohio State University MicroRNA expression profile associated with pancreatic cancer
MX2008012219A (es) * 2006-04-03 2008-10-02 Santaris Pharma As Composicion farmaceutica que comprende oligonucleotidos antisentido anti-miarn.
US20080220423A1 (en) 2006-05-19 2008-09-11 Soren Moller Oligonucleotide probes useful for detection and analysis of microRNA precursors
US9200275B2 (en) 2006-06-14 2015-12-01 Merck Sharp & Dohme Corp. Methods and compositions for regulating cell cycle progression
US20090307788A1 (en) 2006-06-19 2009-12-10 Kobenhavns Universitet Ribozyme mediated stabilization of polynucleotides
US9617581B2 (en) 2006-08-25 2017-04-11 Duke University Methods for in vivo identification of endogenous mRNA targets of MicroRNAs
CA2663962A1 (en) 2006-09-19 2008-03-27 Asuragen, Inc. Mir-15, mir-26, mir-31,mir-145, mir-147, mir-188, mir-215, mir-216, mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
WO2008042231A2 (en) 2006-09-29 2008-04-10 Children's Medical Center Corporation Compositions and methods for evaluating and treating heart failure
US8906870B2 (en) 2006-10-09 2014-12-09 Julius-Maximilians-Universitaet Wuerzberg MicroRNA (miRNA) for the diagnosis and treatment of heart diseases
WO2008147430A2 (en) 2006-10-11 2008-12-04 Nucleonics, Inc. Microrna-formatted multitarget interfering rna vector constructs and methods of using the same
US20100021914A1 (en) 2006-11-23 2010-01-28 Querdenker Aps Oligonucleotides for modulating target rna activity
EP2104735A2 (en) 2006-12-08 2009-09-30 Asuragen, INC. Mir-21 regulated genes and pathways as targets for therapeutic intervention
WO2008073921A2 (en) 2006-12-08 2008-06-19 Asuragen, Inc. Mir-126 regulated genes and pathways as targets for therapeutic intervention
CN101675165A (zh) 2006-12-08 2010-03-17 奥斯瑞根公司 Let-7微小rna的功能和靶标
EP2102341A2 (en) 2006-12-08 2009-09-23 Asuragen, INC. Mirna regulated genes and pathways as targets for therapeutic intervention
EP3536788A1 (en) 2006-12-21 2019-09-11 QIAGEN GmbH Microrna target site blocking oligos and uses thereof
WO2008074328A2 (en) 2006-12-21 2008-06-26 Exiqon A/S Microrna target site blocking oligos and uses thereof
US20090175827A1 (en) 2006-12-29 2009-07-09 Byrom Mike W miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
WO2008109373A1 (en) 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting erbb gene expression and uses thereof
US9043994B2 (en) 2007-03-13 2015-06-02 Massachusetts Institute Of Technology Cre-lox based gene knockdown constructs and methods of use thereof
WO2008116267A1 (en) 2007-03-26 2008-10-02 Crc For Asthma And Airways Ltd Therapeutic targets and molecules
JP5637533B2 (ja) 2007-05-23 2014-12-10 ジーイー ヘルスケア ダーマコン，インク． マイクロ−ｒｎａスキャホールドおよび非天然存在型マイクロ−ｒｎａ
CA2693031A1 (en) 2007-07-18 2009-01-22 The Regents Of The University Colorado Differential expression of micrornas in nonfailing versus failing human hearts
WO2009012263A2 (en) 2007-07-18 2009-01-22 The Trustees Of Columbia University In The City Of New York Tissue-specific micrornas and compositions and uses thereof
US20090092980A1 (en) 2007-07-20 2009-04-09 Christoph Arenz miRNA PROCESSING INHIBITOR EFFICACY ASSAYS AND SUBSTANCES
WO2009044895A1 (ja) 2007-10-03 2009-04-09 Kyowa Hakko Kirin Co., Ltd. 標的遺伝子の発現を抑制する組成物
WO2009043354A2 (en) 2007-10-04 2009-04-09 Santaris Pharma A/S Combination treatment for the treatment of hepatitis c virus infection
JP2011517279A (ja) 2007-10-29 2011-06-02 ユニバーシティ オブ マサチューセッツ 核酸（ｓｉＲＮＡ）送達用の酵母細胞壁粒子（ＹＣＷＰ）多層状ナノ粒子
WO2009058818A2 (en) 2007-10-29 2009-05-07 The Board Of Regents Of The University Of Texas System Compositions comprising a micro-rna and methods of their use in regulating cardiac remodeling
AU2008323652B2 (en) 2007-11-09 2014-02-20 Board Of Regents, The University Of Texas System Micro-RNAs of the miR-15 family modulate cardiomyocyte survival and cardiac repair
WO2009066967A2 (en) * 2007-11-23 2009-05-28 Panagene Inc. Microrna antisense pnas, compositions comprising the same, and methods for using and evaluating the same
CA2717792A1 (en) 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
EP2279267A4 (en) 2008-03-27 2012-01-18 Vascular Biosciences Inc METHOD FOR IDENTIFYING NEW THERAPY CANDIDATES ON GENE EXPRESSION ANALYSIS IN DISEASES RELATED TO VACCINES
EP2105145A1 (en) 2008-03-27 2009-09-30 ETH Zürich Method for muscle-specific delivery lipid-conjugated oligonucleotides
US20100113284A1 (en) 2008-04-04 2010-05-06 Alexander Aristarkhov Small interfering rna (sirna) target site blocking oligos and uses thereof
US20090326049A1 (en) 2008-04-04 2009-12-31 Alexander Aristarkhov Blocking oligos for inhibition of microrna and sirna activity and uses thereof
US8258111B2 (en) 2008-05-08 2012-09-04 The Johns Hopkins University Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
US8222221B2 (en) 2008-06-04 2012-07-17 The Board Of Regents Of The University Of Texas System Modulation of gene expression through endogenous small RNA targeting of gene promoters
WO2010036939A2 (en) 2008-09-26 2010-04-01 University Of Southern California A system for synergistic expression of multiple small functional rna elements
WO2010048585A2 (en) 2008-10-24 2010-04-29 Isis Pharmaceuticals, Inc. Oligomeric compounds and methods
WO2010126355A1 (en) 2009-04-29 2010-11-04 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for counteracting, preventing and/or determining heart failure, or a risk of heart failure
KR20120047892A (ko) 2009-06-08 2012-05-14 미라젠 세러퓨틱스 ｍｉＲＮＡ 억제제 및 유사체를 위한 화학 변형 모티프

Also Published As

Publication number Publication date
JP2015525081A (ja) 2015-09-03
MX2014015641A (es) 2015-07-14
MD20150006A2 (ro) 2015-06-30
EA201590070A1 (ru) 2015-04-30
US20130345288A1 (en) 2013-12-26
CN104540527A (zh) 2015-04-22
AU2013277033A1 (en) 2015-01-22
WO2013192486A1 (en) 2013-12-27
TW201406774A (zh) 2014-02-16
US9163235B2 (en) 2015-10-20
IN2014DN10899A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-09-11
SG11201408460UA (en) 2015-01-29
EP2863956A4 (en) 2016-01-20
EP2863956A1 (en) 2015-04-29
KR20150036140A (ko) 2015-04-07
BR112014032239A2 (pt) 2017-08-01
AR091539A1 (es) 2015-02-11
CA2876105A1 (en) 2013-12-27

Similar Documents

Publication Publication Date Title
HK1209621A1 (en) Inhibitors of the mir-15 family of micro-rnas
WO2012083005A3 (en) Microrna inhibitors comprising locked nucleotides
MX355408B (es) Inhibidores a base de oligonucleotidos que comprenden un motivo de acido nucleico bloqueado.
MX2021015290A (es) Composiciones y metodos para inhibicion de genes para apolipoproteina c-iii (apoc3).
PH12017501501A1 (en) Compositions and methods for inhibiting expression of tmprss6 gene
NZ808402A (en) Modified rnai agents
HK1211317A1 (en) Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders
BR112014025020A2 (pt) composições e métodos para inibição da expressão do gene alas1
UA117098C2 (uk) Сполука, що містить модифікований олігонуклеотид
WO2014028429A3 (en) Enzymes and polymerases for the synthesis of rna
HK1200837A1 (en) Compositions and methods for silencing aldehyde dehydrogenase
WO2012027713A3 (en) Compositions and methods for inhibition of snca
WO2012142313A3 (en) Micro-rna inhibitors and their uses in disease
MX2022001017A (es) Composiciones y metodos para inhibir la expresion del gen de sintasa de acido 5'-aminolevulinico 1 (alas1).
WO2013006558A3 (en) Compositions and methods for treating skeletal myopathy
PL398796A1 (pl) Zastosowanie czasteczek miRNA oraz antagomiru dla miRNA w diagnostyce, zapobieganiu i leczeniu stwardnienia rozsianego
EP2851426A3 (en) Compositions and methods for inhibiting expression of RRM2 genes
NZ728207A (en) Oligonucleotide-based inhibitors comprising locked nucleic acid motif
NZ776080A (en) Modified rnai agents
MA37789A1 (fr) Inhibiteurs de la famille mir-15 de micro-arn